As of 2026-09-21, the Intrinsic Value of Briacell Therapeutics Corp (BCT.TO) is -17.63 CAD. This BCT.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 5.92 CAD, the upside of Briacell Therapeutics Corp is -397.79%.
Based on its market price of 5.92 CAD and our intrinsic valuation, Briacell Therapeutics Corp (BCT.TO) is overvalued by 397.79%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -17.63 - -17.63 | -17.63 | -397.79% |
| P/E | (25.39) - (14.60) | (21.95) | -470.8% |
| DDM - Stable | (31.38) - (86.33) | (58.85) | -1094.2% |
| DDM - Multi | (25.41) - (54.13) | (34.56) | -683.7% |
| Market Cap (mil) | 51.50 |
| Beta | 1.50 |
| Outstanding shares (mil) | 8.70 |
| Enterprise Value (mil) | 44.62 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.77% |
| Cost of Debt | 5.00% |
| WACC | 6.73% |